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Pancreatic cancer (PaCa) is a multifaceted disorder with an extremely poor prognosis. 
There is an urgent need to identify new and safe drugs as well as to develop novel 
tumor-targeted controlled release systems for effective treatment of late stage and 
resistant PaCa. Active targeting via the inclusion of specific ligands on the nanoparticles 
(NPs) is envisioned to provide a powerful therapeutic strategy (1). In this context, 
identification of ligand/receptor systems that enable functionalized NPs efficiently 
target the pancreatic ductal adenocarcinoma (PDAC) holds great promise for the 
development of novel approaches for treatment of PaCa. Plectin-1 (Plec-1) was recently 
identified as specific biomarker to detect PDAC at an early stage (2). Moreover, 
multivalent attachment of small molecular entities can increase specific binding affinity 
and high specificity for PaCa cells (3). On the other hand, altered cellular bioenergetics 
and oxidative stress are emerging hallmarks of many types of cancer including 
pancreatic cancer. Cancer cells are more prone to reactive oxygen species (ROS)-
mediated cell death due to their inherent elevated basal oxidative stress as compared to 
normal cells. In this scenario, we have recently discovered a novel class of potential 
PaCa therapeutics (i.e., DFCs compounds) that exert their cytotoxic effects by 
modulating ROS-mediated cell signaling (4).  
Herein, we present a study on the design and the development of novel DFC-
encapsulated biocompatible polymeric NPs, functionalized with peptides to selectively 
bind to Plec-1 (PTP), or densely decorated by low molecular weight organic molecules 
as alternative targeting ligands (2-ABA), and evaluated a) the impact on ligand binding 
and b) the in vitro antiproliferative efficacy against a panel of PaCa cells. 
 
 
(1) Farokhzad, O.C.; Langer, R. ACS Nano 2009, 3, 16-20 
(2) Bausch, D.; Thomas, S.; Mino-Kenudson, M.; Fernández-del, C.C.; Bauer, T.W.; Williams, M.; 
Warshaw, A.L.; Thayer,  S.P.; Kelly, K.A. Clin. Cancer. Res. 2012, 17, 302-309 
(3) Weissleder, R.; Kelly, K.; Sun, E.Y.; Shtatland, T.; Josephson, L. Nat. Biotechnol. 2005, 23, 1418-
1423 
(4) Pathania, D.; Sechi, M.; Palomba, M.; Sanna, V.; Berrettini, F.; Sias, A.; Taheri. L.; Neamati. N. 
Biochim. Biophys. Acta (General Subjects), 2013, submitted 
